{"id":22734,"date":"2021-05-04T19:38:37","date_gmt":"2021-05-04T18:38:37","guid":{"rendered":"https:\/\/touchneurology.com\/?post_type=media_gallery&#038;p=22734"},"modified":"2021-05-04T19:39:50","modified_gmt":"2021-05-04T18:39:50","slug":"jiwon-oh-aan-2021-fenebrutinib-in-multiple-sclerosis","status":"publish","type":"media_gallery","link":"https:\/\/touchneurology.com\/multiple-sclerosis\/conference-hub\/jiwon-oh-aan-2021-fenebrutinib-in-multiple-sclerosis\/","title":{"rendered":"Jiwon Oh, AAN 2021: Fenebrutinib in Multiple Sclerosis"},"content":{"rendered":"<p><strong>Dr Jiwon Oh <\/strong>(University of Toronto, Canada) caught up with touchNEUROLOGY to discuss investigating fenebrutinib as a potential Multiple Sclerosis therapy.<\/p>\n<p>The abstract entitled: &#8216;The Safety of Fenebrutinib in a Large Population of Patients With Diverse Autoimmune Indications Supports Investigation in Multiple Sclerosis (MS)&#8217; was presented at the American Academy of Neurology Virtual Annual Meeting 2021.<\/p>\n<p><strong>Questions<\/strong>:<\/p>\n<ol>\n<li>What is the rationale for the use of BTK inhibitors in MS? (0:14)<\/li>\n<li>How does fenebrutinib differ from other agents in its class in terms of suitability as an MS therapy? (1:20)<\/li>\n<li>What autoimmune indications were included in your safety analysis? (3:41)<\/li>\n<li>What were the findings of this analysis? (4:30)<\/li>\n<li>What were the conclusions in terms of potential use at high doses in MS patients? (6:51)<\/li>\n<\/ol>\n<p><strong>Disclosures<\/strong>:<\/p>\n<p>Jiwon Oh has received personal compensation for consulting or speaking from EMD-Serono, Sanofi-Genzyme, Biogen-Idec, Novartis, BMS, and Roche, and has\u00a0received research funding from the MS Society of Canada, the National MS Society, Brain Canada, Biogen-Idec, Roche, and EMD-Serono.<\/p>\n<p><strong>Support<\/strong>: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.<\/p>\n<p><em><strong>Filmed as a highlight of AAN Annual Virtual Meeting 2021.<\/strong><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dr Jiwon Oh (University of Toronto, Canada) caught up with touchNEUROLOGY to discuss investigating fenebrutinib as a potential Multiple Sclerosis therapy. The abstract entitled: &#8216;The Safety of Fenebrutinib in a Large Population of Patients With Diverse Autoimmune Indications Supports Investigation in Multiple Sclerosis (MS)&#8217; was presented at the American Academy of Neurology Virtual Annual Meeting [&hellip;]<\/p>\n","protected":false},"featured_media":22735,"template":"","class_list":["post-22734","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-multiple-sclerosis","video_categories-aan-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/22734","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":2,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/22734\/revisions"}],"predecessor-version":[{"id":22737,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/22734\/revisions\/22737"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media\/22735"}],"wp:attachment":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media?parent=22734"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}